Skip to main content

Mónica Sánchez Bartrés

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Mónica Sánchez Bartrés

Institutions of which they are part

Main researcher
Diabetes and Metabolism
Vall Hebron Institut de Recerca

Projects

Individualización de la Monitorización continua de glucosa en la población anciana con diabetes mellitus tipo 2 en función del Estado cognitivo

IP: Monica Sanchez Bartres
Collaborators: Angel Michael Ortiz Zúñiga, Ana Maria Ortiz de Urbina Olive, Judit Amigó Farran, Mercè Abad Martín, Olga Simó Servat, Pedro Alejandro Gil Millán
Funding agency: Sociedad Española de Diabetes
Funding: 20000
Reference: SED/SANCHEZ/2023
Duration: 01/12/2023 - 31/05/2025

Diabetis i metabolisme

IP: Rafael Simó Canonge
Collaborators: Josep A Villena Delgado, Carles Zafon Llopis, Cristina Hernández Pascual, David Martinez Selva, Rosario Pardo Diaz, Angel Michael Ortiz Zúñiga, Andreea Ciudin Mihai, Fiorella Ximena Palmas Candia, Ana Maria Ortiz de Urbina Olive, Monica Sanchez Bartres, Lorena Ramos Pérez, Marc Rivas Agudo, Diabetis i metabolisme, Anna Casteras Román, Alejandra Planas Vilaseca, Betina Biagetti Biagetti, Judit Amigó Farran, Mercè Abad Martín, Marta Comas Martínez, Hugo Ramos Abellan, Rosa Burgos Peláez, David Sabater Martínez, Olga Simó Servat, Patricia Bogdanov Baruj, Maria Llorian Salvador, Enzamaría Fidilio Meli
Funding agency: Agència Gestió Ajuts Universitaris i de Recerca
Funding: 60000
Reference: 2021 SGR 00655
Duration: 01/01/2022 - 30/06/2025

H2O Health Outcomes Observatory

IP: Yolima Cossio Gil
Collaborators: Cristina Hernández Pascual, Natalia Borruel Sainz, Gemma Galán Martinez, Monica Sanchez Bartres, Marta Ferri Peradalta, Rafael Simó Canonge, Joan Carles Peiró Ruiz
Funding agency: The Innovative Medicines Initiative
Funding: 1097257.5
Reference: H2O_IMI2-2020
Duration: 01/10/2020 - 30/09/2025

Related news

Funding has been obtained for 43 projects under the calls for Health R&D&I Projects, Health Technology Development, and Independent Clinical Research

The work represents a paradigm shift in the clinical approach to this chronic, multifactorial disease, based on the clinical context of each patient and not only on weight loss.

The results of a phase 3 clinical trial show that orforglipron reduces body weight by an average of 11% and improves cardiovascular risk factors.

Related professionals

Gema Ariceta Iraola

Gema Ariceta Iraola

Head of group
Kidney Physiopathology
Read more
Yuri Lara Taranchenko

Yuri Lara Taranchenko

Predoctoral researcher
Reconstructive Surgery of the Locomotor System
Read more
Marylin Riveiro Vilaboa

Marylin Riveiro Vilaboa

Neurotraumatology and Neurosurgery Research Unit (UNINN)
Read more
Marc Tort Lacambra

Marc Tort Lacambra

Predoctoral researcher
Ophtalmology
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.